يعرض 1 - 10 نتائج من 42 نتيجة بحث عن '"Gironella Mesa, Mercedes"', وقت الاستعلام: 0.99s تنقيح النتائج
  1. 1
    دورية أكاديمية
  2. 2
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, de la Rubia J, Jarque I Hematology Department, H.U. i Politècnic La Fe. Valencia, Spain. School of Medicine and Dentistry, Catholic University of Valencia, Valencia, Spain. Centro de Investigación Biomédica en Red de Cáncer, CIBERONC CB16/12/00284, Instituto de Salud Carlos III. Madrid, Spain. González B Hematology Department, H.U. de Canarias, San Cristóbal de La Laguna, Santa Cruz de Tenerife, Spain. Cruz-Jentoft AJ Geriatric Unit, Hospital Universitario Ramón y Cajal (IRYCIS), Madrid, Spain. Iglesias L Hematology Department, C.H.U. A Coruña. A Coruña, Spain. Persona EP Hematology Department H. U, Vitoria-Gasteiz, Álava, Spain. Gironella M Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: Journal of Geriatric Oncology;14(1); https://doi.org/10.1016/j.jgo.2022.10.016Test; de la Rubia J, González B, Cruz-Jentoft AJ, Iglesias L, Jarque I, Persona EP, et al. Geriatric assessment in hematology scale predicts treatment tolerability in older patients diagnosed with hematological malignancies: The RETROGAH study. J Geriatr Oncol. 2023 Jan;14(1):101401.; https://hdl.handle.net/11351/9326Test; 000946209600001

  3. 3
    دورية أكاديمية
  4. 4
    دورية أكاديمية
  5. 5
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Jiménez M, Roldán E, Gironella M, Fox L, Orti G, Barba P, Valcárcel D, Bosch F, Abrisqueta P Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Fernández-Naval C, Pumarola T, Esperalba J Servei de Microbiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Villacampa G Oncology Data Science (ODysSey) Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Martinez-Gallo M, Hernández M Servei d’Immunologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Departament de Biologia Cel·lular, Fisiologia i Immunologia, Universitat Autònoma de Barcelona, Bellaterra, Spain. Medina-Gil D, Peralta-Garzón S, Pujadas G, Hernández C, Pagès C, Crespo M Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Cabirta A, Catalá E, Valentín M, Marín-Niebla A Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Orfao A Department of Medicine and Cytometry General ServiceNucleus, Cancer Research Centre (IBMCC/CSIC/USAL/IBSAL), Salamanca, Spain. González M Department of Hematology, University Hospital of Salamanca (HUS/IBSAL), CIBERONC–CB16/12/00233 and Center for Cancer Research–IBMCC (USAL-CSIC), Salamanca, Spain. Campins M Servei de Medicina Preventiva i Epidemiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Ruiz-Camps I Servei de Malalties Infeccioses, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: Blood Advances;6(3); https://doi.org/10.1182/bloodadvances.2021006101Test; Jimenez M, Roldan E, Fernandez-Naval C, Villacampa G, Martinez-Gallo M, Medina-Gil D, et al. Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies. Blood Adv. 2022 Feb 8;6(3):774–84.; https://hdl.handle.net/11351/8614Test; 000754263400007

  6. 6
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Benitez Hidalgo O, Martinez Garcia MF, Gironella Mesa M, Bosch Albareda F Experimental Hematology Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Servei d’Hematologia, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Bescos Cabestre A Servei de Neurocirurgia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Juarez Gimenez JC Servei de Farmàcia Hospitalària, Vall d'Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: Clinical Case Reports;10(5); https://doi.org/10.1002/ccr3.5848Test; Benitez Hidalgo O, Martinez Garcia MF, Bescos Cabestre A, Juarez Gimenez JC, Gironella Mesa M, Bosch Albareda F. Neurosurgery in a patient with severe hemophilia B: an experience using eftrenonacog alfa as perioperative management. Clin Case Reports. 2022 May;10(5):e05848.; https://hdl.handle.net/11351/8056Test; 000798984900001

  7. 7
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Puig N Hematology Department, Hospital Universitario de Salamanca (HUSAL), IBSAL, IBMCC (USAL-CSIC), CIBERONC, Salamanca, Spain. Hernández MT Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain. Rosiñol L Hematology Department, Hospital Clinic, IDIBAPS, Barcelona, Spain. González E Hospital Universitario de Cabueñes, Gijón, Spain. de Arriba F Hospital Morales Meseguer, IMIB-Arrixaca, Universidad de Murcia, Murcia, Spain. Oriol A Institut Català d’Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona, Spain. Gironella M Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: Blood Cancer Journal;11; https://doi.org/10.1038/s41408-021-00490-8Test; Puig N, Hernández MT, Rosiñol L, González E, de Arriba F, Oriol A, et al. Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial. Blood Cancer J. 2021 May 21;11:101.; https://hdl.handle.net/11351/6807Test; 000657750600003

  8. 8
    دورية أكاديمية
  9. 9
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Medina A, Jiménez C, Sarasquete ME, González M, Chillón MC, Balanzategui A Hospital Universitario de Salamanca (HUSAL), IBSAL, IBMCC (USAL-CSIC), CIBERONC, Salamanca, Spain. Gironella M Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: Blood Cancer Journal;10; https://doi.org/10.1038/s41408-020-0283-8Test; info:eu-repo/grantAgreement/ES/PE2013-2016/PI15%2F01956; info:eu-repo/grantAgreement/ES/PE2013-2016/CB16%2F12%2F00233; info:eu-repo/grantAgreement/ES/PE2013-2016/CPII18%2F00028; Medina A, Jiménez C, Sarasquete ME, González M, Chillón MC, Balanzategui A, et al. Molecular profiling of immunoglobulin heavy-chain gene rearrangements unveils new potential prognostic markers for multiple myeloma patients. Blood Cancer J. 2020 Feb 6;10:14.; https://hdl.handle.net/11351/6280Test; 000512747500001

  10. 10
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: Blood Cancer Journal;10; https://doi.org/10.1038/s41408-020-00372-5Test; Martínez-López J, Mateos MV, Encinas C, Sureda A, Hernández-Rivas JÁ, Lopez de la Guía A, et al. Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality. Blood Cancer J. 2020 Oct 19;10:103.; https://hdl.handle.net/11351/6282Test; 000586453500001